Kiniksa Pharmaceuticals International, plc
KNSA
NASDAQ·Healthcare·Medical - Pharmaceuticals·Mkt cap $5.9B
$77.91
▼ -3.18%
P/E
72.81
Mkt Cap
$5.9B
52-Wk Range
$35.20–$82.94
52-Week Range
$35.20 - $82.94
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 113.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Specialized focus on rare inflammatory diseases with limited competition
- Proprietary monoclonal antibody technology platform
- Experienced management team with deep pharma expertise
- ARCALYST market approval and revenue generation
Bear Case
2 risks
- Low volatility (beta 0.1).
- Growth premium of 2.8x vs sector peers. Elevated but may be justified by growth trajectory.
Growth
Moderate growth ahead
ARCALYST market expansion and label extensions
Value
Growth premium of 2.8x vs sector peers. Elevated but may be justified by growth trajectory.
Momentum
Hot
+58.9% over 3m
Quality
Strong
High-growth business (59% revenue growth, 54% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying KNSA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 27, 2026
JUL 28, 2026
Reported EPS of $0.30 vs $0.30 consensus (+0.2% surprise). Revenue of $243.6M vs $226.5M expected (+7.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+0.2%
Revenue trend · last 8Q
—
—
—
+44%
+61%
+65%
+56%
+55%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$112.2M
$122.5M
$137.8M
$156.8M
$180.9M
$202.1M
$214.3M
$243.6M
Margins · last 8Q
Gross
90.3%
Operating
11.2%
Profit
10.4%
Wall Street consensus
6 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$72.00
▼ -7.6% vs $77.91
Latest: Citi · Jul 29, 2026
1 analyst covering
vs Industry
How KNSA stacks vs Medical - Pharmaceuticals
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.